4.1 Therapeutic indications
Azathioprine is used in facilitating the survival of organ and tissue transplants, where it is mainly used as an immunosuppressant.
Azathioprine is used in the treatment of patients exhibiting the following conditions, where it has been shown to have a marked therapeutic effect: chronic active hepatitis, severe rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic thrombocytopenic purpura, acquired haemolytic anaemia and severe cases of specified dermatological diseases (pemphigus vulgaris, dermatomyositis, polyarteritis nodosa, pyoderma gangrenosa) when these conditions are: (a) refractory to corticosteroids or (b) when corticosteroids are contra-indicated or (c) when controlled by corticosteroids in dosages which are producing severe side-effects. In patients who are experiencing such side-effects, the aim of azathioprine treatment is to reduce the required maintenance dose of steroids.
Azathioprine is used in the treatment of pemphigus and rheumatoid arthritis where it has significant therapeutic activity when used without corticosteroids.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).